Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Ensysce Biosciences, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 18 | 21 | +3 |
| Shares | 3.38M | 5.47M | +2.09M (+61.8%) |
| Value | $15.9M | $6.23M | −$9.64M (−60.8%) |
New holders (7)
Institutions that held Ensysce Biosciences, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 1,875,367 | $2.14M | 0.29% |
| Renaissance Technologies LLC | 287,661 | $328.0K | 0.00% |
| Powell Investment Advisors, LLC | 50,000 | $57.0K | 0.03% |
| Virtu Financial LLC | 24,630 | $28.0K | 0.00% |
| Covington Capital Management | 100 | $0 | 0.00% |
| Cutler Group LP | 100 | $0 | 0.00% |
| FNY Investment Advisers, LLC | 20 | $0 | 0.00% |
Sold out (4)
Institutions that held Ensysce Biosciences, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Goldman Sachs Group Inc | 170,648 | $802.0K |
| Jane Street Group, LLC | 16,733 | $79.0K |
| JPMorgan Chase & Co | 1,314 | $6.00K |
| Bank of America Corp | 91 | $0 |